Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Determine the overall response rate (ORR) of bemcentinib plus chemotherapy
(nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic adenocarcinoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
BerGenBio ASA Translational Genomics Research Institute Triligent International